The Omega-3 Fatty Acid Eicosapentaenoic Acid Accelerates Disease Progression in a Model of Amyotrophic Lateral Sclerosis
Open Access
- 19 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e61626
- https://doi.org/10.1371/journal.pone.0061626
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive fatal neurodegenerative disease characterised by loss of motor neurons that currently has no cure. Omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA), have many health benefits including neuroprotective and myoprotective potential. We tested the hypothesis that a high level of dietary EPA could exert beneficial effects in ALS. The dietary exposure to EPA (300 mg/kg/day) in a well-established mouse model of ALS expressing the G93A superoxide dismutase 1 (SOD1) mutation was initiated at a pre-symptomatic or symptomatic stage, and the disease progression was monitored until the end stage. Daily dietary EPA exposure initiated at the disease onset did not significantly alter disease presentation and progression. In contrast, EPA treatment initiated at the pre-symptomatic stage induced a significantly shorter lifespan. In a separate group of animals sacrificed before the end stage, the tissue analysis showed that the vacuolisation detected in G93A-SOD1 mice was significantly increased by exposure to EPA. Although EPA did not alter motor neurone loss, EPA reversed the significant increase in activated microglia and the astrocytic activation seen in G93A-SOD1 mice. The microglia in the spinal cord of G93A-SOD1 mice treated with EPA showed a significant increase in 4-hydroxy-2-hexenal, a highly toxic aldehydic oxidation product of omega-3 fatty acids. These data show that dietary EPA supplementation in ALS has the potential to worsen the condition and accelerate the disease progression. This suggests that great caution should be exerted when considering dietary omega-3 fatty acid supplements in ALS patients.Keywords
This publication has 59 references indexed in Scilit:
- Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1G93A mice modelNeurobiology of Disease, 2011
- The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compressionBMC Genomics, 2010
- Misfolded Mutant SOD1 Directly Inhibits VDAC1 Conductance in a Mouse Model of Inherited ALSNeuron, 2010
- Sustained sensorimotor impairments after endothelin-1 induced focal cerebral ischemia (stroke) in aged ratsExperimental Neurology, 2010
- Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acidProstaglandins, Leukotrienes & Essential Fatty Acids, 2010
- Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant miceAmyotrophic Lateral Sclerosis, 2009
- CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALSProceedings of the National Academy of Sciences, 2008
- Diagnosis and management of motor neurone diseaseBMJ, 2008
- SOD1 and Amyotrophic Lateral Sclerosis: Mutations and OligomerizationPLOS ONE, 2008
- Omega-3 Fatty Acids Improve Recovery, whereas Omega-6 Fatty Acids Worsen Outcome, after Spinal Cord Injury in the Adult RatJournal of Neuroscience, 2006